Sector footprint
$1.7M in exports
Reported chemicals exports in 2024 across 38 qualifying HS6 products.
Sector export playbook ยท HS 28-38
Bahamas Chemicals exports
where capability meets demand
Explore Bahamas's HS 28-38 product portfolio, buyer markets, growth signals, and diversification opportunities. Use this guide to prioritize research, not to treat calculated indicators as guaranteed sales.
Sector exports$1.7M2024 reported value
Products38Qualifying HS6 products
Buyer markets14Markets represented
Average CAGR+25.9%Product-level growth signal
Global sector size$430.5BReported buyer imports
Chemicals capability
How strong is Bahamas in this sector?
Compare exporter scale with product breadth, buyer demand, growth, and destination reach. A large sector does not remove the need for product, compliance, pricing, and buyer validation.
Global demand
$430.5B buyer imports
The sector's reported buyer import base provides context for product and market prioritization.
How to use the guide
Find the next credible move
Start with products that combine demand and exporter capability, then validate standards, route economics, buyers, and competition.
Product portfolio
Which products anchor the sector?
Each HS6 product is ranked by calculated opportunity and shown with reported market size, exporter exports, growth, and destination reach.
| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
|---|---|---|---|---|---|---|
| HS 300490Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $186.3B | $342.7K | $70.5B | +3.5% | 10 | +0.0% |
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $82.5B | $6.2 | $30.7B | -22.2% | 2 | +0.0% |
| HS 293719Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $16.4B | $199.9 | $29.5B | +98.9% | 1 | +0.0% |
| HS 300214Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $22.4B | $6.3 | $25.9B | -22.1% | 2 | +0.0% |
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $891.2K | $11.7B | -21.1% | 2 | +0.0% |
| HS 330300Perfumes and toilet waters | $11.3B | $5.4K | $6.1B | +2.2% | 6 | +0.0% |
| HS 330210Odoriferous substances and mixtures: of a kind used in the food or drink industries | $4.4B | $38.1K | $6.0B | +19.3% | 1 | +0.0% |
| HS 382200Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $13.1B | $7.2K | $5.2B | -3.2% | 4 | +0.0% |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | $7.9B | $3.5K | $4.7B | +10.9% | 1 | +0.0% |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $10.9B | $960.5 | $4.6B | -8.1% | 4 | +0.0% |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $8.5B | $990.0 | $4.3B | +74.2% | 1 | +0.0% |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $9.3B | $7.1K | $3.6B | +5.0% | 1 | +0.0% |
| HS 293499Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $6.2B | $100.0 | $2.8B | -17.6% | 1 | +0.0% |
| HS 300390Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $8.5K | $2.2B | +716.4% | 2 | +0.0% |
| HS 300420Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $6.7K | $2.0B | +17.9% | 1 | +0.0% |
| HS 284190Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $1.7B | $16.8K | $1.7B | +34.6% | 1 | +0.0% |
| HS 300290Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $3.9B | $7.2K | $1.7B | +7.0% | 2 | +0.0% |
| HS 284410Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $12.9K | $1.4B | +28.1% | 1 | +0.0% |
| HS 300432Medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale | $2.8B | $30.3K | $1.3B | -50.5% | 2 | +0.0% |
| HS 293722Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $2.5K | $1.3B | -55.0% | 1 | +0.0% |
| HS 290110Acyclic hydrocarbons: saturated | $916.4M | $0.7 | $1.3B | -41.8% | 1 | +0.0% |
| HS 340220Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $3.1B | $128.0K | $1.2B | +43.0% | 2 | +0.0% |
| HS 382600Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $1.9B | $14.1 | $1.1B | +19.0% | 1 | +0.0% |
| HS 293134Organo-inorganic compounds: organo-phosphorus derivatives, sodium-3-(hydroxysilyl)propyl methylphosphonate | $590.5M | $15.3 | $958.1M | -64.4% | 1 | +0.1% |
| HS 290220Cyclic hydrocarbons: benzene | $1.4B | $35.1K | $895.3M | -1.2% | 1 | +0.0% |
| HS 300449Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, packaged for retail sale | $1.5B | $67.1 | $841.5M | -15.5% | 1 | +0.0% |
| HS 330290Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | $1.3B | $208.0 | $803.3M | +127.1% | 1 | +0.0% |
| HS 281410Ammonia: anhydrous | $1.1B | $348.0 | $748.4M | +54.3% | 1 | +0.0% |
| HS 292250Amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function | $1.1B | $44.1K | $699.0M | +37.2% | 1 | +0.0% |
| HS 284440Radioactive elements, isotopes, compounds, n.e.c. in heading no. 2844 alloys, dispersions (including cermets), ceramic products and mixtures containing these elements, isotopes or compounds: radioactive residues | $927.2M | $1.2K | $685.2M | +7.4% | 1 | +0.0% |
| HS 381800Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $1.5B | $0.8 | $645.9M | -16.3% | 1 | +0.0% |
| HS 300213Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale | $961.6M | $1.6 | $643.7M | -66.9% | 1 | +0.0% |
| HS 340600Candles, tapers and the like | $1.0B | $386.0 | $640.9M | -3.1% | 1 | +0.0% |
| HS 300660Pharmaceutical goods: chemical contraceptive preparations based on hormones or spermicides | $1.2B | $38.5 | $604.6M | -9.2% | 1 | +0.0% |
| HS 360410Pyrotechnic products: fireworks | $518.2M | $74.8K | $603.8M | +13.0% | 1 | +0.0% |
| HS 293729Steroidal hormones, their derivatives and structural analogues: other than cortisone, hydrocortisone, prednisone (dehydrocortisone), prednisolone (dehydrohydrocortisone), halogenated derivatives of corticosteroidal hormones, oestrogen and progestogens | $320.8M | $9.3K | $584.1M | +78.9% | 1 | +0.3% |
| HS 330749Perfumes and deodorizors: perfuming or deodorizing preparations for rooms, (excluding those which operate by burning) | $676.1M | $130.0 | $579.1M | +3.4% | 1 | +0.0% |
| HS 310530Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | $733.2M | $450.6 | $547.9M | +44.7% | 1 | +0.0% |
Best markets
Where does sector demand concentrate?
Markets are ranked by calculated opportunity across the qualifying products in this sector view.
USA
USA, Puerto Rico and US Virgin Islands
35 products represented in the sector.
$154.9B$268.3B reported buyer importsCHE
Switzerland, Liechtenstein
1 products represented in the sector.
$27.7B$41.0B reported buyer importsDEU
Germany
10 products represented in the sector.
$16.8B$39.9B reported buyer importsCAN
Canada
4 products represented in the sector.
$6.3B$10.7B reported buyer importsGBR
United Kingdom
3 products represented in the sector.
$5.6B$16.8B reported buyer importsITA
Italy
2 products represented in the sector.
$5.4B$15.6B reported buyer importsNLD
Netherlands
1 products represented in the sector.
$5.3B$10.5B reported buyer importsFRA
France
3 products represented in the sector.
$4.4B$14.2B reported buyer importsKOR
Republic of Korea
1 products represented in the sector.
$1.1B$3.8B reported buyer importsSGP
Singapore
1 products represented in the sector.
$1.1B$1.9B reported buyer importsAUS
Australia
1 products represented in the sector.
$751.8M$4.5B reported buyer importsCHN
China
1 products represented in the sector.
$750.5M$818.5M reported buyer importsGrowth stars
Which products show the strongest growth?
Average product-level CAGR is a screening signal. Confirm the latest trend, base effects, buyer quality, and commercial feasibility before acting.
| Product | Average CAGR | Opportunity | Markets |
|---|---|---|---|
| HS 300390Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | +716.4% | $2.2B | 2 |
| HS 330290Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | +127.1% | $803.3M | 1 |
| HS 293719Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | +98.9% | $29.5B | 1 |
| HS 293729Steroidal hormones, their derivatives and structural analogues: other than cortisone, hydrocortisone, prednisone (dehydrocortisone), prednisolone (dehydrohydrocortisone), halogenated derivatives of corticosteroidal hormones, oestrogen and progestogens | +78.9% | $584.1M | 1 |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | +74.2% | $4.3B | 1 |
| HS 281410Ammonia: anhydrous | +54.3% | $748.4M | 1 |
| HS 310530Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | +44.7% | $547.9M | 1 |
| HS 340220Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | +43.0% | $1.2B | 2 |
| HS 292250Amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function | +37.2% | $699.0M | 1 |
| HS 284190Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | +34.6% | $1.7B | 1 |
Diversification opportunities
Which products reach the widest buyer base?
Destination count is a simple breadth indicator. It does not measure destination concentration or guarantee resilience.
HS 300490
Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale
10 markets$70.5B calculated opportunityHS 330300
Perfumes and toilet waters
6 markets$6.1B calculated opportunityHS 382200
Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material
4 markets$5.2B calculated opportunityHS 330499
Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations)
4 markets$4.6B calculated opportunityHS 300215
Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale
2 markets$30.7B calculated opportunityHS 300214
Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale
2 markets$25.9B calculated opportunityHS 293359
Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof
2 markets$11.7B calculated opportunityHS 300390
Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale)
2 markets$2.2B calculated opportunityFrequently asked questions
Using the Chemicals export playbook
Practical guidance for interpreting sector scale, growth, product breadth, and buyer markets.
How strong is Bahamas in this sector?
Compare sector exports, product breadth, buyer markets, growth, and global demand. These signals identify research priorities rather than guarantee market access.
What are growth stars?
Products with higher average reported growth in the screened rows. Validate the time period, base effects, buyer demand, and current exporter position.
What does diversification mean here?
Products reaching more buyer markets in the screened data. Destination breadth is useful context but does not replace concentration, route, or buyer analysis.
Data source
OECD trade statistics with CEPII context
OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). OECD BIMTS is the primary trade series for this view. Supporting bilateral trade context uses CEPII BACI bilateral trade flows (202601) under Etalab 2.0 Open Licence. Yugalinks presents derived views of reported observations and calculated indicators. Data terms: OECD Terms & Conditions.